Drug Substance Development & Manufacturing
The successful development of biologics requires a robust and scalable manufacturing strategy that ensures consistent product quality throughout the product lifecycle. As a critical stage between process development and final drug product manufacturing, drug substance production plays a key role in translating innovative biologics into reliable therapeutic solutions. Protheragen provides integrated solutions covering process optimization, scale-up development, technology transfer, clinical material production, and commercial manufacturing support.
Overview of Drug Substance Development & Manufacturing
Drug Substance (DS) development and manufacturing encompasses the development, optimization, and production of the active biological component of a therapeutic product prior to final drug product manufacturing. For biologics, DS production involves integrated upstream cell culture, downstream purification, process characterization, and analytical evaluation to establish a robust and scalable manufacturing process.
From early development to commercial production, drug substance manufacturing requires consistent process performance, reliable scale-up strategies, and comprehensive quality assessment to ensure product quality, safety, and supply continuity. A well-designed DS manufacturing process provides the foundation for successful clinical development and long-term commercial availability of biologic medicines.
Fig.1 Overview of the TOs processing with upstream and downstream operations. (Abe A, et al., 2025)
Our Services
The development of high-quality oligonucleotide drug substances requires robust process strategies, scalable manufacturing capabilities, and comprehensive quality evaluation throughout the development lifecycle. From early API process development to clinical-stage production, establishing reliable drug substance manufacturing processes is essential for ensuring product consistency, purity, and regulatory readiness.
Protheragen provides integrated oligonucleotide drug substance development and manufacturing services to support diverse nucleic acid therapeutic programs, including oligonucleotide APIs and RNA-based drug substances. Our capabilities cover process optimization, manufacturing support, and analytical characterization to help partners efficiently advance oligonucleotide candidates from development stages toward clinical applications.
01
Oligonucleotide API Development
Protheragen provides comprehensive oligonucleotide API development services to support the transformation of candidate molecules into scalable and manufacturable drug substances. Our team focuses on establishing optimized synthesis routes, refining purification strategies, and developing robust process parameters to ensure consistent product quality. Through systematic evaluation of critical process parameters (CPPs) and critical quality attributes (CQAs), Protheragen helps clients develop reliable manufacturing processes suitable for preclinical studies, clinical development, and regulatory submission.
02
Oligonucleotide API Manufacturing
Protheragen offers flexible oligonucleotide API manufacturing services for a wide range of nucleic acid therapeutics, including ASO, siRNA, CpG oligonucleotides, PMO, and other chemically modified oligonucleotides. By integrating advanced solid-phase synthesis platforms, purification technologies, and comprehensive quality control systems, we support the production of high-quality oligonucleotide drug substances from laboratory scale to clinical supply. Our manufacturing capabilities enable efficient scale-up while maintaining product consistency, purity, and regulatory compliance.
03
RNA Drug Substance Manufacturing
Protheragen provides specialized RNA drug substance manufacturing services to support the growing demand for RNA-based therapeutics, including mRNA, siRNA, and other RNA molecules. Our integrated platform covers RNA synthesis process development, purification optimization, analytical characterization, and manufacturing scale-up. By applying advanced synthesis and purification technologies, Protheragen helps clients overcome challenges associated with RNA stability, structural integrity, and impurity control, enabling the development of reliable RNA drug substance production processes.
Quality Control and Characterization Support
To ensure consistent drug substance quality, Protheragen integrates comprehensive analytical testing throughout development and manufacturing. Analytical characterization includes:
- Identity confirmation
- Purity analysis
- Sequence verification
- Related substance analysis
- Residual solvent testing
- Residual reagent analysis
- Molecular weight determination
- Stability evaluation
These analytical capabilities support quality assessment, regulatory documentation, and IND/BLA submission requirements.
Flexible Manufacturing Solutions for Oligonucleotide Therapeutics
Protheragen provides customized manufacturing strategies according to project requirements, supporting:
| Development Stage |
Manufacturing Solutions |
|
Preclinical Development
|
Research-grade oligonucleotide production
Process feasibility evaluation
Candidate optimization support
|
|
Clinical Development
|
GMP-like and GMP drug substance manufacturing
Process validation support
Regulatory documentation assistance
|
|
Commercial Manufacturing
|
Scalable production solutions
Long-term supply support
Quality system integration
|
Why Choose Protheragen
- Comprehensive Oligonucleotide Expertise
Experience covering multiple oligonucleotide modalities, including ASO, siRNA, PMO, CpG, and RNA therapeutics.
- Integrated Development Platform
Supporting the complete workflow from sequence design, process development, API manufacturing, and analytical characterization.
- Flexible Scale-up Capability
Providing manufacturing solutions from early research quantities to clinical and commercial production scales.
Helping customers generate high-quality documentation and data packages for regulatory submissions.
- Quality-Focused Manufacturing
Implementing rigorous quality control strategies to ensure product consistency and reliability.
From early-stage process development to clinical and commercial manufacturing, Protheragen provides integrated oligonucleotide drug substance development and manufacturing solutions to support the advancement of innovative nucleic acid therapeutics. With expertise in oligonucleotide API development, scalable synthesis, purification optimization, RNA manufacturing, and GMP-compliant production, we help partners establish reliable manufacturing pathways and accelerate their drug development programs. Whether you are developing ASO, siRNA, RNA-based therapeutics, or other emerging oligonucleotide modalities, Protheragen offers flexible and customized CDMO solutions tailored to your project requirements. Contact us to discuss your oligonucleotide CDMO requirements and explore tailored solutions for your next-generation therapeutics.
Reference
- Abe A, et al. "Overview and Recent Advances in the Purification and Isolation of Therapeutic Oligonucleotides" Org. Process Res. Dev. 2025; 29 (1): 15–33.
